Salute e Benessere

Mendus to Host KOL Event to Review Phase 2 Data with Vididencel in Acute Myeloid…

Press Release Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced it will host a virtual KOL Event on December 14, 2023 at 9:00 AM ET, featuring Dr. Arjan van de Loosdrecht, Professor of Hematology at Amsterdam UMC and Principal Investigator of the ADVANCE II trial, who will discuss the current treatment landscape for patients with Acute Myeloid Leukemia (AML) and the development of Mendus' lead product...
Nasdaq GlobeNewswire
04/12/2023

Transactions in Zealand Pharma shares and/or related securities by persons…

Company announcement – No. 42 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 4, 2023–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or...
Nasdaq GlobeNewswire
04/12/2023

Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot…

Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ ®Primary endpoint met with 97% seroresponse rate 24 months after a single vaccinationAntibody levels remained high and well above the seroresponse threshold, further supporting the anticipated long-term durability of the immune response No safety concerns identified in long-term follow upSaint-Herblain (France), December 4, 2023– Valneva SE (Nasdaq: VALN;...
Nasdaq GlobeNewswire
04/12/2023

Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE®…

Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE ®and DONESTA ®in ChinaMithra signs binding Head of Terms for a twenty-year partnership with Gedeon-Richter for the development and commercialization of ESTELLE ® and DONESTA® in ChinaMithra to receive EUR 4.5 million in combined milestone payments at signature of the license agreements with additional combined regulatory milestones of EUR 1.2 millionMithra eligible to...
Nasdaq GlobeNewswire
04/12/2023

Roche enters into a definitive merger agreement to acquire Carmot Therapeutics…

Carmot Therapeutics's R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche's in-house assetsLead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbidities Under the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments...
Nasdaq GlobeNewswire
04/12/2023

Commercial Court hearing to examine the takeover offer scheduled for December…

Commercial Court hearing to examine the takeover offer scheduled for December 18, 2023Paris, France, December 4, 2023 – 7:00 am (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces that the Paris Commercial Court will hold a hearing to examine the takeover offer received by the court-appointed administrators and...
Nasdaq GlobeNewswire
04/12/2023

Hyloris announces US FDA approval for Podofilox Gel

Hyloris announces US FDA approval for Podofilox GelProduct previously referenced as HY-016, targeting genital and perianal wartsUS Commercialization by partner Padagis to start in December 2023Second U.S. market approval of the year after Maxigesic® IVLiège, Belgium – 04 December 2023 – 7AM CET – Regulated information – inside information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL),a specialty biopharma company committed to addressing unmet medical needs through...
Nasdaq GlobeNewswire
04/12/2023

EndoQuest™ Robotics Closes $42 Million in Financing to Advance Endoluminal…

The financing round was led by the Company's legacy investors, CE Ventures Limited and McNair Interests Ltd., along with Puma Venture Capital LLC as a new investor. This significant investment reflects a strong vote of confidence in EndoQuest's vision to revolutionize endoluminal procedures through cutting-edge robotic technology. The newly acquired capital will be instrumental in driving key initiatives, including further research and development, regulatory milestones, commercialization…
PR Newswire
04/12/2023

First Patient Dosed in European Named Patient (Early Access) Program for…

The program follows the completion of Telix's successful global Phase III ZIRCON study (Zirconium in Renal Cancer Oncology, ClinicalTrials.gov Identifier: NCT03849118), which reported positive results in November 2022, meeting all co-primary and secondary endpoints.1 The program follows the completion of Telix's successful global Phase III ZIRCON study ( Zi rconium inR enalC ancerOn cology, ClinicalTrials.gov Identifier:NCT03849118 ), which reported positive results inNovember 2022,...
PR Newswire
04/12/2023

The 3rd International Medical Innovation and Cooperation Forum convenes in…

The Forum's objective is to further enhance the regional, diversified, integrated, and sustainable cooperation framework, solidifying its role as a bridge for communication and interaction among countries engaged in China's Belt and Road Initiative and SCO member states. Leveraging the strength of the SCO and ASEAN, it seeks to broaden global medical innovation and cooperation, optimize the allocation of medical resources, and elevate the global healthcare standard. This will enable individuals…
PR Newswire
04/12/2023

Junshi Biosciences Announces New Chemical Entity Application for Toripalimab…

This NCE application was submitted through Project Orbis, an initiative of the FDA's Oncology Center of Excellence (OCE) that provides a collaborative mechanism and framework among the FDA and regulatory partners in other countries and regions, for concurrent submission and review of oncology drugs. At present, seven other regulatory agencies have joined Project Orbis, including the TGA, Singapore Health Sciences Authority (HSA), Health Canada (HC), MHRA, etc.Project Orbis currently...
Nasdaq GlobeNewswire
02/12/2023

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)PARIS, Dec.01, 2023(GLOBE NEWSWIRE) -- Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 11/30/202371,751,20177,686,109For further information on Cellectis, please contact:Media contact: Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com Investor...
Nasdaq GlobeNewswire
01/12/2023

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Regulated InformationLeuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CETOxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation 1it has received transparency notifications as follows: Oxurion received a first transparency notification on November 22, 2023, from Atlas...
Nasdaq GlobeNewswire
01/12/2023

Number of voting rights as of November 30, 2023

Nicox SA Société anonyme with a registered capital of € 50,170,498 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On December 1st, 2023, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l'AMF) As of November 30, 2023 Total number of shares...
Nasdaq GlobeNewswire
01/12/2023

Pharmaceutical Excipients Market Worth $14.9 Billion | MarketsandMarkets

Browse in-depth TOC on "Pharmaceutical Excipients Market" Browse in-depth TOC on "Pharmaceutical Excipients Market" 562 - Tables 51 - Figures 373 - Pages Pharmaceutical Excipients Market Scope: The organic chemicals segment dominated the market share in 2022 for the product segment. Based on product, the global pharmaceutical excipients market is categorised into organic chemicals, inorganic chemicals and other chemicals. Organic chemicals are mainly chemicals...
PR Newswire
01/12/2023

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and…

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFOOutstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSORetiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handoverChristopher Roberts, Interim Chief Financial Officer, confirmed in role on a permanent basis Lausanne, Switzerland, December 1, 2023– AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...
Nasdaq GlobeNewswire
01/12/2023

Sports Eyewear Market to Reach $8.9 Billion, Globally, by 2027 at 7.3% CAGR…

Request Sample Copy of Report: https://www.alliedmarketresearch.com/request-sample/287485 Request Sample Copy of Report:https://www.alliedmarketresearch.com/request-sample/287485 Prime determinants of growth The rise in awareness of eye protection is driving the growth of the market. However, the market for sports eyewear is significantly constrained by customization challenges. On the other hand, the growth in technological advancements is creating lucrative opportunities for...
PR Newswire
01/12/2023

Calliditas announces additions to the management team

"Jonathan has been instrumental in building up the US operations for Calliditas in every way and he will be sorely missed by all. We wish him the very best. We welcome Brian to the team and look forward to working with him as we embark on the next chapter of our journey," said Renée Aguiar-Lucander, CEO Calliditas. "Jonathan has been instrumental in building up the US operations for Calliditas in every way and he will be sorely missed by all. We wish him the very best. We welcome…
PR Newswire
01/12/2023

itel Unveils New Logo, Redefining Smart Life Service in Emerging Markets

As part of its ongoing commitment to enhancing the quality of life for consumers in emerging economies, itel has collaborated with DesignStudio, a global design team based in Australia, to craft a youthful, energetic, and forward-looking logo. This significant departure from the previous design retains the iconic speech bubble, symbolizing itel's dedication to communication and connectivity. As part of its ongoing commitment to enhancing the quality of life for consumers in emerging…
PR Newswire
01/12/2023

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium…

In cooperation with several leading breast cancer research organizations, Exact Sciences will present late-breaking data and a study included in the SABCS press program. Results from Puerto Rico will also detail germline findings for a cohort of women, most of whom had a personal or familial history of breast cancer. The results suggest a distinct genetic background for hereditary cancer predisposition in the study population. In cooperation with several leading breast cancer research...
PR Newswire
01/12/2023

Invitation to presentation of Sectra's six-month interim report 2023/2024

To participate, follow the instructions on Sectra's website investor.sectra.com/q2report2324. The broadcast will be made available on the same webpage after the conference. To participate, follow the instructions on Sectra's websiteinvestor.sectra.com/q2report2324. The broadcast will be made available on the same webpage after the conference. Participation will take place via Microsoft Teams. Questions can be posed using the chat function or by sending questions in advance via email to...
PR Newswire
01/12/2023

SKF increases localization rate in the Americas and Asia; closes factory in…

By transferring the supply of products to SKF's factories in Puebla, Mexico, Pune, India, and Shanghai ATC, China, these businesses will be closer to its existing customers. In addition, it will enable these businesses to expand by attracting new local business opportunities. This also supports the Group's Automotive strategy and the ongoing portfolio re-positioning towards the electric vehicle drivetrain and commercial vehicle segments. By transferring the supply of products to SKF's…
PR Newswire
01/12/2023

"Click" for Joy, Connect for a Home: SONGMICS HOME Officially Launches Public…

"Cats and abandoned animals as a whole, obviously require physical and medical care, but also emotional care, because most of them have experienced abandonment, sometimes have lived on the streets. That's why they have more difficulty forming a bond. It's also very important to work on emotional care so that they can be adopted by a family afterward." said Marjolaine Mathiaud, Manager of Partnerships and Events of La SPA. "Cats and abandoned animals as a whole, obviously require…
PR Newswire
01/12/2023

Acute Myocardial Infarction Treatment Market to Show Immense Growth at a CAGR of…

Key Takeaways from the Acute Myocardial Infarction Market Report Key Takeaways from the Acute Myocardial Infarction Market Report Discover which therapies are expected to grab the major acute myocardial infarction market share @Acute Myocardial Infarction Market Report Acute Myocardial Infarction Overview Acute myocardial infarction is myocardial necrosis caused by a sudden blockage of a coronary artery. Acute myocardial infarction, together with unstable angina, is referred...
PR Newswire
30/11/2023
Altri  Comunicati